We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
AGI | LSE:AGI | London | Ordinary Share | IE00B0YT0Q82 | ORD EUR0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.25 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMAGI
RNS Number : 9352X
AGI Therapeutics plc
22 February 2012
AGI Therapeutics plc ('AGI')
Holding in Company
AGI was notified on 22 February 2012 that as of 16 February 2012 Aravis Therapeutics Limited has a shareholding of 60,784,191 ordinary shares of EUR0.10 each representing 90.17 per cent of AGI's entire issued share capital.
Contact Information
AGI Therapeutics
David G. Kelly, Chief Financial Officer Tel: +353 1 449 3254
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUUSNRUVAUUAR
1 Year AGI Chart |
1 Month AGI Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions